Patents Assigned to Oslo University Hospital HF
-
Patent number: 11725248Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.Type: GrantFiled: April 20, 2017Date of Patent: August 15, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg, Oregon Health & Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and ResearchInventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
-
Patent number: 11646099Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.Type: GrantFiled: December 13, 2019Date of Patent: May 9, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Boatd of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barceloa, Institut D'Investigacions Biomédiques Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft feuer medizinische Forshung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic FoundationInventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
-
Patent number: 11419874Abstract: The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.Type: GrantFiled: November 23, 2018Date of Patent: August 23, 2022Assignee: OSLO UNIVERSITY HOSPITAL HFInventors: Jan Magnus Aronsen, Jonas Skogestad
-
Patent number: 11028444Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.Type: GrantFiled: April 27, 2018Date of Patent: June 8, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of WürzburgInventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Patent number: 10697975Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.Type: GrantFiled: June 22, 2017Date of Patent: June 30, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic de Barcelona, Julius-Maximilians-University of Würzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of LondonInventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine S. Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa M. Rimsza, Thomas Miller, Thomas Grogan, Elias Campo Guerri, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emilio Montserrat, Victor Moreno, Andreas Zettl, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend B. Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister
-
Publication number: 20200143906Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.Type: ApplicationFiled: January 17, 2020Publication date: May 7, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health & Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HFInventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs (Deceased), Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
-
Publication number: 20200105364Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.Type: ApplicationFiled: December 13, 2019Publication date: April 2, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut D? Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft fuer medizinische Forschung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic FoundationInventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
-
Patent number: 10607717Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.Type: GrantFiled: November 5, 2014Date of Patent: March 31, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health and Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HFInventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
-
Publication number: 20190153539Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.Type: ApplicationFiled: April 20, 2017Publication date: May 23, 2019Applicants: The United States of America, as represented by the secretary, Dep. of Health and Human Service, British Columbia Cancer Agency Branch, Julius-Maximilians - University of Würzburg, Oregon Health and Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, Board of Regents of the University of Nebraska, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and ResearchInventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
-
Publication number: 20180245165Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.Type: ApplicationFiled: April 27, 2018Publication date: August 30, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Arizona Regents on Behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of WürzburgInventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Patent number: 9970059Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.Type: GrantFiled: November 13, 2014Date of Patent: May 15, 2018Assignees: The United States of America, as represented by the Secretary, Department of Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of WürzburgInventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Publication number: 20180011106Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.Type: ApplicationFiled: June 22, 2017Publication date: January 11, 2018Applicants: The United States of America, as represented by he Secretary, Department of Health and Human Servi, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic de Barcelona, Julius-Maximilians-University of Wurzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of LondonInventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine S. Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa M. Rimsza, Thomas Miller, Thomas Grogan, Elias Campo Guerri, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emilio Montserrat, Victor Moreno, Andreas Zetti, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend B. Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister
-
Patent number: 9403812Abstract: The present invention relates to compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear ?-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.Type: GrantFiled: June 29, 2015Date of Patent: August 2, 2016Assignee: OSLO UNIVERSITY HOSPITAL HFInventors: Daniel Holsworth, Jo Waaler, Ondrej Machon, Stefan Krauss, Andrey Edward Voronkov
-
Patent number: 9096587Abstract: The present invention relates to compounds of formula (I), to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear ?-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.Type: GrantFiled: December 8, 2011Date of Patent: August 4, 2015Assignee: OSLO UNIVERSITY HOSPITAL HFInventors: Daniel Holsworth, Jo Waaler, Ondrej Machon, Stefan Krauss, Andrey Edward Voronkov
-
Publication number: 20150132297Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.Type: ApplicationFiled: November 13, 2014Publication date: May 14, 2015Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary and Westfield College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of WuerzburgInventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Patent number: 8883827Abstract: The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.Type: GrantFiled: June 7, 2010Date of Patent: November 11, 2014Assignee: Oslo University Hospital HFInventors: Daniel Holsworth, Jo Waaler, Ondrej Machon, Stefan Krauss
-
Publication number: 20140031374Abstract: The present invention relates to compounds of formula (I), to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear ?-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.Type: ApplicationFiled: December 8, 2011Publication date: January 30, 2014Applicant: OSLO University Hospital, HFInventors: Daniel Holsworth, Jo Waaler, Ondrej Machon, Stefan Krauss, Andrey Edward Voronkov
-
Publication number: 20120208828Abstract: The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.Type: ApplicationFiled: June 7, 2010Publication date: August 16, 2012Applicant: OSLO UNIVERSITY HOSPITAL HFInventors: Daniel Holsworth, Jo Waaler, Ondrej Machon, Stefan Krauss
-
Patent number: 8131475Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.Type: GrantFiled: July 25, 2006Date of Patent: March 6, 2012Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents of Behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic, Julius-Maximilians-University of Wuerzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of LondonInventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa Rimsza, Thomas Miller, Thomas Grogan, Elias Campo, Silvia M Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emili Montserrat, Victor Moreno, Andreas Zettl, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend Smeland, Stein Kvaløy, Harald Holte, Jan Delabie, T. Andrew Lister
-
Publication number: 20110195064Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.Type: ApplicationFiled: June 5, 2009Publication date: August 11, 2011Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Bloard of Regents on behalf of the University of Arizona, Queen Mary and Westfiled College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Mazimilians-University of WuerzburgInventors: Lisa Rimsza, Andrew T. Lister, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott